We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.
- Authors
Beasley, Georgia M; Riboh, Jonathan C; Augustine, Christina K; Zager, Jonathan S; Hochwald, Steven N; Grobmyer, Stephen R; Peterson, Bercedis; Royal, Richard; Ross, Merrick I; Tyler, Douglas S
- Abstract
Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate. ADH-1 is a cyclic pentapeptide that disrupts N-cadherin adhesion complexes. In a preclinical animal model, systemic ADH-1 given with regional melphalan demonstrated synergistic antitumor activity, and in a phase I trial with M-ILI it had minimal toxicity.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 9, p1210
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.32.1224